EPCAM and nasopharyngeal carcinoma: A Phase 1 clinical trial (NCT02915445) targeting epithelial cell adhesion molecule (EpCAM) in solid tumours, including NPC, showed promising antitumour efficacy and an acceptable safety profile, with two patients showing a partial response and three experiencing more than 23 months of progression-free survival (PFS) (80).